139 related articles for article (PubMed ID: 38797791)
1. Clinical breast exam contribution to breast cancer diagnosis in BRCA mutation carriers vs. average to intermediate risk women.
Menes TS; Zippel D; Sklair-Levy M; Friedman E; Bernstein-Molho R; Faermann R; Madorsky Feldman D
Breast Cancer Res Treat; 2024 May; ():. PubMed ID: 38797791
[TBL] [Abstract][Full Text] [Related]
2. Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers.
Fong A; Cass I; John C; Gillen J; Moore KM; Gangi A; Walsh C; Li AJ; Rimel BJ; Karlan BY; Amersi F
Am Surg; 2020 Oct; 86(10):1243-1247. PubMed ID: 33106023
[No Abstract] [Full Text] [Related]
3. Breast cancer surveillance following ovarian cancer in BRCA mutation carriers.
John CS; Fong A; Alban R; Gillen J; Moore KM; Walsh CS; Li AJ; Rimel BJ; Amersi F; Cass I
Gynecol Oncol; 2022 Jan; 164(1):202-207. PubMed ID: 34862065
[TBL] [Abstract][Full Text] [Related]
4. Pregnancy Associated Breast Cancer Among Israeli BRCA1/BRCA2 Carriers in a High-Risk Clinic.
Faermann R; Friedman E; Kaidar-Person O; Brodsky M; Neiman OH; Shalmon A; Gotlieb M; Yagil Y; Samocha D; Feldman DM; Weidenfeld J; Sklair-Levy M
Acad Radiol; 2023 Feb; 30(2):248-254. PubMed ID: 35527100
[TBL] [Abstract][Full Text] [Related]
5. Contribution of clinical breast exam to cancer detection in women participating in a modern screening program.
Menes TS; Coster D; Coster D; Shenhar-Tsarfaty S
BMC Womens Health; 2021 Oct; 21(1):368. PubMed ID: 34666735
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer risk in
Nañez A; Stram DA; Bethan Powell C; Garcia C
Gynecol Oncol Rep; 2022 Feb; 39():100899. PubMed ID: 34917730
[TBL] [Abstract][Full Text] [Related]
7. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
Warner E; Plewes DB; Hill KA; Causer PA; Zubovits JT; Jong RA; Cutrara MR; DeBoer G; Yaffe MJ; Messner SJ; Meschino WS; Piron CA; Narod SA
JAMA; 2004 Sep; 292(11):1317-25. PubMed ID: 15367553
[TBL] [Abstract][Full Text] [Related]
8. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
9. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer surveillance in BRCA positive Sri Lankan women: health equity for a high-risk group at a limited resource setting.
Liyanage UA; Sirisena ND; Deshapriya PC; Dissanayake VHW
BMC Womens Health; 2023 Nov; 23(1):636. PubMed ID: 38017478
[TBL] [Abstract][Full Text] [Related]
11. The added value of mammography in different age-groups of women with and without BRCA mutation screened with breast MRI.
Vreemann S; van Zelst JCM; Schlooz-Vries M; Bult P; Hoogerbrugge N; Karssemeijer N; Gubern-Mérida A; Mann RM
Breast Cancer Res; 2018 Aug; 20(1):84. PubMed ID: 30075794
[TBL] [Abstract][Full Text] [Related]
12. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers.
Grindedal EM; Heramb C; Karsrud I; Ariansen SL; Mæhle L; Undlien DE; Norum J; Schlichting E
BMC Cancer; 2017 Jun; 17(1):438. PubMed ID: 28637432
[TBL] [Abstract][Full Text] [Related]
13. Differences between screen-detected and interval breast cancers among BRCA mutation carriers.
Pilewskie M; Zabor EC; Gilbert E; Stempel M; Petruolo O; Mangino D; Robson M; Jochelson MS
Breast Cancer Res Treat; 2019 May; 175(1):141-148. PubMed ID: 30673971
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for failure to detect a cancer during clinical breast examinations (United States).
Bobo JK; Lawson HW; Lee NC
Cancer Causes Control; 2003 Jun; 14(5):461-8. PubMed ID: 12946041
[TBL] [Abstract][Full Text] [Related]
15. Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer.
Straub MM; Podoll MB; David SN; Wiesner GL; Desouki MM
Ann Diagn Pathol; 2018 Oct; 36():28-30. PubMed ID: 30055521
[TBL] [Abstract][Full Text] [Related]
16. 'Earlier than Early' Detection of Breast Cancer in Israeli
Anaby D; Shavin D; Zimmerman-Moreno G; Nissan N; Friedman E; Sklair-Levy M
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370730
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer detection among Irish BRCA1 & BRCA2 mutation carriers: a population-based study.
Walsh EM; Farrell MP; Nolan C; Gallagher F; Clarke R; McCaffrey JA; Kennedy MJ; Barry M; Kell MR; Gallagher DJ
Ir J Med Sci; 2016 Feb; 185(1):189-94. PubMed ID: 25673166
[TBL] [Abstract][Full Text] [Related]
18. Estimating disparities in breast cancer screening programs towards mortality, case fatality, and DALYs across BRICS-plus.
Mubarik S; Malik SS; Yanran Z; Hak E; Nawsherwan ; Wang F; Yu C
BMC Med; 2023 Sep; 21(1):299. PubMed ID: 37653535
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of breast screening strategies in a high risk breast and ovarian cancer clinic.
Knisely AT; Stewart ME; Garcia C; Thomas MH; Modesitt SC; Ring KL
Gynecol Oncol Rep; 2020 Aug; 33():100587. PubMed ID: 32490124
[TBL] [Abstract][Full Text] [Related]
20. Breast ultrasonography (BU) in the screening protocol for women at hereditary-familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories?
Cortesi L; Canossi B; Battista R; Pecchi A; Drago A; Dal Molin C; Toss A; De Matteis E; Marchi I; Torricelli P; Cascinu S
Int J Cancer; 2019 Mar; 144(5):1001-1009. PubMed ID: 30098212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
